|1.43|| +0.04 / +2.88%|
Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV). In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV). Aviragen Therapeutics was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
|Joseph M. Patti||President, Chief Executive Officer & Director|
|Mark P. Colonnese||Chief Financial Officer & Executive Vice President|
|Anna Novotney-Barry||Vice President-Clinical Development|
|John H. Vernachio||Vice President-Preclinical Development|
|Peter J. Azzarello||Secretary, Chief Accounting Officer & VP|